全球大麻素市场规模、份额、趋势和成长分析报告（2026-2034）

预计大麻素市场将从 2025 年的 578.5 亿美元成长到 2034 年的 3,638.8 亿美元，2026 年至 2034 年的复合年增长率为 22.67%。

受监管改革、临床研究以及消费者对包括CBD在内的大麻素产品日益增长的兴趣的推动，全球大麻素市场正在快速扩张。北美和欧洲部分地区将大麻合法化用于医疗用途，为製药和健康产业铺平了道路；同时，消费者对局部用药、膳食补充剂和机能性食品的广泛接受，也创造了多元化的收入来源。对种植、萃取和配方技术的投资，正在提升产业能力和产品多样性，从而加速市场成长和商业性认可。

关键成长要素包括越来越多的临床和临床前证据表明大麻素在疼痛管理、癫痫和其他适应症方面具有潜力，以及多个司法管辖区的放鬆管制创造了商业机会。萃取、纯化和均质化技术的进步，以及奈米乳剂和经皮给药系统等递送技术的创新，正在提高生物利用度和消费者信心。大型公司的垂直整合和策略併购活动也促进了供应链的专业化和整个产业品质标准的提升。

未来前景乐观，但存在区域差异。如果后期临床试验证实疗效，药用级大麻素疗法可望占据高价值市场。同时，随着剂量标准化和标籤清晰化，消费市场也将日益成熟。随着大型企业寻求垂直整合的供应链，以及监管机构强调品管和可追溯性，预计产业整合将会出现。给药平台和临床研究的持续创新将影响治疗方法的普及及其长期成长轨迹。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球大麻素市场：依产品类型划分

• 市场分析、洞察与预测
• 大麻二酚
• 四氢大麻酚
• 大麻酚
• 其他的

第五章 全球大麻素市场：依应用领域划分

• 市场分析、洞察与预测
• 医疗应用（慢性疼痛管理、神经系统疾病管理、肿瘤学等）
• 非医疗用途

第六章：全球大麻素市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路商店

第七章 全球大麻素市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Mylan NV（Viatris Inc.）
  • Alkem Labs
  • GW Pharmaceuticals Plc（Jazz Pharmaceuticals）
  • Tilray Inc
  • Aurora Cannabis Inc
  • Canopy Growth Corporation
  • The Cronos Group
  • Endoca
  • Cannoid LLC
  • Medical Marijuana Inc

The Cannabinoids Market size is expected to reach USD 363.88 Billion in 2034 from USD 57.85 Billion (2025) growing at a CAGR of 22.67% during 2026-2034.

The global cannabinoids market has expanded rapidly as legal reform, clinical research, and consumer interest in CBD and other cannabinoid products converge. Medical legalization in parts of North America and Europe opened pharmaceutical and wellness channels, while broad consumer adoption of topicals, nutraceuticals, and functional foods created diverse revenue streams. Investment across cultivation, extraction, and formulation technologies increased industrial capacity and product variety, accelerating market growth and commercial visibility.

Key drivers include increasing clinical and preclinical evidence for cannabinoids' potential in pain management, epilepsy, and other indications, plus regulatory loosening in several jurisdictions that create commercial opportunities. Advancements in extraction, purification, and consistent formulation-along with delivery innovations such as nanoemulsions and transdermal systems-improve bioavailability and consumer confidence. Vertical integration by larger players and strategic M&A activity also professionalize supply chains and raise quality standards across the sector.

Future prospects are robust but regionally varied: pharmaceutical-grade cannabinoid therapeutics could capture high-value market segments if late-stage trials confirm efficacy, while consumer markets will mature with standardized dosing and clearer labeling. Expect consolidation as large firms pursue vertically integrated supply chains and as regulators emphasize quality control and traceability. Continued innovation in delivery platforms and clinical research will shape therapeutic adoption and long-term growth trajectories.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Cannabidiol
• Tetrahydrocannabinol
• Cannabinol
• Others

By Application

• Medicinal Use (Chronic Pain, Neurological Disorders Management, Oncology, Others)
• Non-medical Use

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Stores

COMPANIES PROFILED

• Mylan NV Viatris Inc, Alkem Labs, GW Pharmaceuticals plc Jazz Pharmaceuticals, Tilray Inc, Aurora Cannabis Inc, Canopy Growth Corporation, The Cronos Group, Endoca, Cannoid LLC, Medical Marijuana Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANNABINOIDS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Cannabidiol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tetrahydrocannabinol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cannabinol Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANNABINOIDS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Medicinal Use (Chronic Pain, Neurological Disorders Management, Oncology, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-medical Use Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANNABINOIDS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANNABINOIDS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANNABINOIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Mylan N.V. (Viatris Inc.)
  • 9.2.2 Alkem Labs
  • 9.2.3 GW Pharmaceuticals Plc (Jazz Pharmaceuticals)
  • 9.2.4 Tilray Inc
  • 9.2.5 Aurora Cannabis Inc
  • 9.2.6 Canopy Growth Corporation
  • 9.2.7 The Cronos Group
  • 9.2.8 Endoca
  • 9.2.9 Cannoid LLC
  • 9.2.10 Medical Marijuana Inc